Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Senate, House Panels Release Clean Device User-Fee Discussion Draft

Executive Summary

Lawmakers emphasized the need for a swift reauthorization of a combined US FDA device and drug user-fee reauthorization bill before the end of July, and released a clean discussion draft April 14 that mirrors the agreements reached by industry and the agency last summer.


Related Content

Lab Professionals Oppose Draft Dx Reform Bill; Lab, IVD Industry Ready To Work With Congress
House Subcommittee Grills Shuren On Facility Inspection Shortfalls
Risks Of Missing Reauthorization Deadline Highlighted At User-Fee Hearing
Device Standards Provision In Cures Bill Could Speed Up 510(k) Clearances
MDUFA IV Fees Unveiled: Changes For 510(k)s, Small Business, De Novos
FDA Reattempts Guidance On Third-Party 510(k) Review Program
MDUFA IV Takes Shape: A Catalogue Of Draft Commitments





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst